On September 30, 2026 Hummingbird Diagnostics GmbH, a molecular diagnostics company specializing in blood-based small RNA analysis for precision oncology, reported that data from a new collaborative study will be presented at the ESMO (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Building on Hummingbird’s expertise in early cancer detection, the study explores whether RNA biomarker analysis may provide biological insights related to prognosis and molecular disease status in patients with locally advanced, non-resectable stage III lung cancer.
The work was conducted in collaboration with investigators from LungenClinic Grosshansdorf, Germany, and F.D. Roosevelt University General Hospital of Banská Bystrica, Slovakia. The findings will be presented at the congress.
Presentation details
Title: A Single-RNA Biomarker Prognostic/MRD Assay for Locally Advanced, Non-Resectable Stage III Lung Cancer
Presentation number: 4323P
Presentation type: Poster presentation
Category: Translational Research and Biomarkers
Date and time: Friday, October 23, 2026, 15:15-16:00 CEST
(Press release, Hummingbird Diagnostics, SEP 30, 2026, View Source [SID1234671200])